HP Fiscal Q4 Non-GAAP Earnings, Revenue Rise -- Shares Drop After Hours-March 2024-www.financetom.com

HP Fiscal Q4 Non-GAAP Earnings, Revenue Rise -- Shares Drop After Hours

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

HP Fiscal Q4 Non-GAAP Earnings, Revenue Rise -- Shares Drop After Hours

Nov 26, 2024 1:55 PM

04:41 PM EST, 11/26/2024 (MT Newswires) -- HP (HPQ) reported fiscal Q4 non-GAAP diluted earnings late Tuesday of $0.93, up from $0.90 a year earlier.

Analysts polled by FactSet expected $0.93.

Revenue for the quarter ended Oct. 31 was $14.06 billion, up from $13.82 billion a year earlier.

Analysts surveyed by FactSet expected $13.99 billion.

The company said it expects fiscal Q1 non-GAAP diluted earnings of $0.70 to $0.76. Analysts surveyed by FactSet expect $0.85.

HP expects fiscal year 2025 non-GAAP diluted earnings of $3.45 to $3.75. Analysts surveyed by FactSet expect $3.61.

HP shares were down more than 7% in recent after-hours activity.

Previous page： Renasant to Acquire The First Bancshares for $1.2 Billion Next page： BioNTech's cancer drug meets primary endpoint in Phase 2 trial

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Renasant to Acquire The First Bancshares for $1.2 Billion

Jul 30, 2024

06:55 AM EDT, 07/30/2024 (MT Newswires) -- Renasant ( RNST ) will acquire The First Bancshares (FBMS) in an all-stock deal worth roughly $1.2 billion, expanding its footprint in the US southeast. Investors of The First will receive one share of Renasant ( RNST ) stock for each share owned, the lenders said in a joint statement late Monday. This...

BioNTech's cancer drug meets primary endpoint in Phase 2 trial

Jul 30, 2024

(Reuters) - COVID-19 vaccine maker BioNTech's cancer drug candidate BNT111 showed significant improvement in the response rate in patients with advanced melanoma during a Phase 2 trial, the German company said on Tuesday. The trial met its primary endpoint, with data demonstrating a statistically significant improvement in the overall response rate in patients treated with the mRNA immunotherapy candidate BNT111...

Leidos Holdings' Q2 Non-GAAP Earnings, Revenue Increase

Jul 30, 2024

06:52 AM EDT, 07/30/2024 (MT Newswires) -- Leidos Holdings ( LDOS ) reported Q2 non-GAAP earnings Tuesday of $2.63 per diluted share, up from $1.80 per share a year earlier. Analysts surveyed by Capital IQ expected $2.27. Revenue for the quarter ended June 28 was $4.13 billion, up from $3.84 billion a year earlier. Analysts polled by Capital IQ expected...

Pfizer raises annual profit forecast after better-than-expected COVID sales

Jul 30, 2024

(Reuters) - U.S. drugmaker Pfizer ( PFE ) raised its annual profit forecast on Tuesday after posting better-than-expected sales for its COVID vaccine and antiviral treatment. New Jersey-based Pfizer ( PFE ) now expects annual profit to be in the range of $2.45 to $2.65 per share, compared with its prior profit forecast of $2.15 to $2.35 per share. With...